NICE has recommended that Janssen’s Darzalex (daratumumab) should be reimbursed on an interim basis by the Cancer Drugs Fund in pre-treated multiple myeloma, after months of wrangling.
Stopping a cancer trial is either a very good, or very bad thing – and luckily for Ipsen the former was the case after a liver cancer trial of its Cabometyx pill was curtailed because of th
